Published in Oncology Business Week, May 30th, 2004
The research signals major progress towards understanding which patients are likely to show significant tumor shrinkage in response to treatment with Iressa, the novel treatment for NSCLC targeted at epidermal growth factor tyrosine kinase (EGFR-TK). Two independent research groups in the U.S. suggest that patients who achieve tumor shrinkage of greater than 50% with Iressa are those where the site coding for EGFR-TK has been changed as a result of one or more mutations...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week